

Date:12thFebruary, 2021

To,
The Secretary,
BOMBAY STOCK EXCHANGE LIMITED,
1st Floor, New Trading Ring
Rotunda Building, P.J.Towers,
Dalal Street,
Mumbai-400001.

Scrip Code:524564

Dear Sir,

Sub: Intimation under Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding outcome of Board Meeting

In compliance with Regulation 33 & 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Un-Audited Financial Results for the Third Quarter and Nine months ended 31st December 2020 which have been reviewed by the Audit Committee and approved by the Board at their meetings held on today i.e., 12thFebruary 2021 and also the Limited Review Report furnished by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 3.30 PM and concluded at 5 p.m.

We would request you to please take note of the same.

Thanking you sir,

For GAYATRI BIOORGANICS LIMITED

C.V. Rayudu
Whole Time Director





GAYATRI

GAYATRI BIOORGANICS LIMITED
STATEMENT OF UN -AUDITED FINANCIALS RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020
 (□ in Lakhs unless otherwise stated)

Sr. No	Particulars	Quarter Ended			Nine Months ended		Year ended
		December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Continuing Operations						
1	Revenue from operations (Refer Note 5)	-	-	4.57	-	6.07	6.37
2	Other Income	-	-	4.57	-	6.07	6.37
3	Total Revenue from operations (1+2)	-	-	4.57	-	6.07	6.37
4	Expenses (Refer Note 5)						
	Cost of Materials Consumed	-	-	-	-	-	-
	Changes in Inventories of Finished Goods and Work in Progress	-	-	-	-	-	-
	Employee Benefits Expenses	7.12	7.14	7.03	21.36	20.84	28.07
	Finance Cost	0.00	-	-	0.03	-	0.58
	Depreciation and Amortisation Expenses	-	-	-	-	-	-
	Other Expenses (Including Excise expense)	4.10	4.75	3.49	13.60	27.79	32.85
	Total Expenses	11.22	11.89	10.52	34.99	48.63	61.50
5	Profit/(Loss) before exceptional and extraordinary items and tax (3-4)	(11.22)	(11.89)	(5.95)	(34.99)	(42.56)	(55.13)
6	Add/(Less): Exceptional Items	-	-	-	-	-	-
7	Profit / (loss) before tax for the period / year (5-6)	(11.22)	(11.89)	(5.95)	(34.99)	(42.56)	(55.13)
8	Tax Expense	-	-	-	-	12.41	-
9	Profit/(Loss) from continuing operations for the period / year (7-8)	(11.22)	(11.89)	(5.95)	(34.99)	(54.97)	(55.13)
	Discontinuing Operations						
10	Profit/(Loss) from discontinuing operations (Refer Note 5)	-	-	-	-	8,511.46	8,502.15
	Add/(Less): Exceptional Items (Refer Note 5)	-	-	-	-	-	-
11	Tax expense of discontinuing operations (Refer Note 5)	-	-	-	-	-	-
12	Profit/(Loss) from discontinuing operations after tax for the period / year (10-11)	-	-	-	-	8,511.46	8,502.15
13	Net Profit/(Loss) for the period / year (9+12)	(11.22)	(11.89)	(5.95)	(34.99)	8,456.50	8,447.01
14	Discontinuing Operations						
	Other Comprehensive Income (net of Tax)						
	Items that will not be reclassified to Statement of Profit and Loss						
	(a) Remeasurement of employee benefit obligation	-	-	-	-	-	-
	(b) Income tax relating to above item	-	-	-	-	-	-
15	Total Comprehensive Income/(Loss) for the period / year (After tax) (13+14)	(11.22)	(11.89)	(5.95)	(34.99)	8,456.50	8,447.01
16	Paid-up Equity Share Capital	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81
17	Other Equity	-	-	-	-	-	-
18	Earnings per share in □ for discontinued operations (annualised except for quarter)						
	Basic	(0.01)	(0.02)	(0.01)	(0.04)	10.73	10.72
	Diluted	(0.01)	(0.02)	(0.01)	(0.04)	10.73	10.72
	(see accompanying notes to the financial results)						

e.v. Ramyada




NOTES

- 1 The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meeting held on February 12, 2021
- 2 The above financial results are extracted from the Audited Financial Statements of the Company, which are prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder.
- 3 With effect from April 1, 2018, the Company has adopted Ind AS 115 – “Revenue from contracts with customers” under the full retrospective approach. Accordingly, the comparatives have been adjusted to give the effect of Ind AS 115. The effect on adoption of Ind AS 115 was insignificant on the financial results.
- 4 The figures for the quarter ended March 31, 2020 are balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the 3rd Quarter ended December 31, 2020, 2nd quarter ended September 30, 2020 and December 31, 2019 respectively.
- 5 The Company has entered into a Business Transfer Agreement (BTA) in November 2016 for transfer of its business undertaking of manufacturing and selling of starch and its derivatives along with its units namely "Unit 1 situated at NH-9, Nandi Kandi Village, Sadasivpet mandal, Medak Dist. Telangana and Unit 2 situated at Balabadrapuram Village, Biccavole Mandal, East Godavari Dist. Andhra Pradesh" on a “slump sale” basis subject fulfilment of certain conditions as mentioned in BTA. Operations of Unit-1 are carried out in the Company till March 31, 2019 while operation of Unit-2 are carried out till November 30, 2018. The Company have recognise gain arising on transfer of business undertaking on completion of various conditions precedent as mentioned in BTA after the transfer of Assets and Liabilities on August 14, 2019.
- 6 The financial statements have been prepared on a going concern basis based upon Comfort letter given by the promoters of the Company for any other business to be continued by them in the future.
- 7 The Company doesn't have more than one segment. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 8 The figures for the corresponding previous period have been regrouped/reclassified/restated wherever necessary to make them comparable with the current year's classification.

**By order of the Board
For Gayatri Bioorganics Limited**

C.V. Rayudu
C V Rayudu
Whole Time Director
DIN: 03536579



Place: Hyderabad
Date: February 12, 2021



Independent Auditors Review Report on the Quarterly and Year to date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

To
The Board of Directors
Gayatri Bioorganics Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Bioorganics Limited (the Company) for the quarter ended 31st December, 2020 and year to date from 1st April, 2020 to 31st December, 2020 (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Rao & Associates
Chartered Accountants
FRN: 009399S



(G. Nageswara Rao)
Partner
Membership No.207300

Place: Hyderabad
Date: 12.02.2021
UDIN:21207300AAAAMS9759

for Publication

GAYATRI BIOORGANICS LIMITED

CIN: L24110TG1991PLC013512

Registered office: B3, Third floor, 6-3-1090, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad - 500 082

Website: www.gayatribioorganics.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2020

Sr. No.	Particulars	STANDALONE					
		Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
1	Total Income from Operations	-	-	-	-	-	6.37
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(11.22)	(11.89)	(5.95)	(34.99)	(54.97)	(55.13)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(11.22)	(11.89)	(5.95)	(34.99)	8,511.46	8,447.01
4	Net Profit / (Loss) for the period after tax (after Exceptional items)	(11.22)	(11.89)	(5.95)	(34.99)	8,511.46	8,447.01
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(11.22)	(11.89)	(5.95)	(34.99)	8,456.49	8,447.01
6	Equity Share Capital	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81
7	Earnings Per Share (of ₹ 10/- each) (not annualised)						
	Basic (In ₹)	(0.01)	(0.02)	(0.01)	(0.04)	10.73	10.72
	Diluted (In ₹)	(0.01)	(0.02)	(0.01)	(0.04)	10.73	10.72

NOTES:

- The above unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on February 12, 2021. The Statutory Auditors of the Company have carried out Limited Review of the Standalone and consolidated financial results.
- The above is an extract of the detailed format of Quarter and Nine Months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015. The full format of the same is available on the websites of the Stock Exchange(s) www.bseindia.com and on company's website www.gayatribioorganics.com

Place : Hyderabad

Date: 12th February, 2021

E.V. Ramprasad



Regd. & Corp. Office :

Gayatri Bioorganics Limited, B1, 1st Floor, 6-3-1090, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad 500 082, Telangana

CIN NO : L24110TG1991PLC013512

T +91 40 6610 0111 / 6610 0222

F +91 40 6610 0333

E info@gayatribioorganics.com
 gayatribioorganics@gmail.com
 www.gayatribioorganics.com